Breast cancer death rates in the United States are on the decline for women of all racial and ethnic groups. Research advancements, such as the identification of genetic changes in breast tumors that could lead to the development of targeted therapies, are helping push the numbers down. Cutting-edge exploration like this is taking place at Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center.
Beyond Breast Cancer Awareness, a panel discussion on advancements in breast cancer genetics, research, and treatment, will feature experts on the molecular level of breast cancer, clinical trials, advanced treatments, and hereditary and other risk factors for breast cancer. The program will feature a scientist, medical oncologist, genetic counselor, and breast cancer survivor to answer your questions.
Ann Stock, Ph.D., professor, Rutgers Center for Advanced Biotechnology and Medicine; member, Rutgers Cancer Institute of New Jersey Director’s Leadership Council
Shridar Ganesan, M.D., Ph.D., associate director for translational science, section chief, molecular oncology, and Omar Boraie Chair in Genomic Science, Rutgers Cancer Institute of New Jersey; professor of medicine and pharmacology, Rutgers Robert Wood Johnson Medical School
Sherry Grumet, M.A, M.S., L.G.C., LIFE Center program director, Rutgers Cancer Institute of New Jersey
Deborah L. Toppmeyer, M.D., professor of medicine, Rutgers Robert Wood Johnson Medical School; chief medical officer, Division of Medical Oncology, and director, Stacy Goldstein Breast Center, Rutgers Cancer Institute of New Jersey
Tuesday, October 27, 2020
7:00 PM – 8:00 PM
Register to receive the link and event password to attend.